オプションチェーンは、Vivani Medicalの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Vivani Medicalの市場センチメントを評価します。.

Vivani Medical (NASDAQ:VANI) 株価情報, オプションチェーン

Vivani Medical

Vivani Medical Inc is a preclinical-stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division.

Vivani Medical Inc

Vivani Medical Inc Warrants (14/03/2024)

Vanilla Network

Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) has outperformed the market over the past 20 years by 1.81% on an annualized basis producing an average annual return of 10.01%. Currently, Nike has a market capitalization of $115.16 billion. 
Buying $1000 In NKE: If an investor had bought $1000 of NKE stock 20 years ago, it would be worth $6,789.21 today based on a price of $77.37 for NKE at the time of writing.
<h3>Nike's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734651013_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In Nike 20 Years Ago Would Be Worth This Much Today

Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) has outperformed the market over the past 15 years by 14.86% on an annualized basis producing an average annual return of 26.48%. Currently, Chipotle Mexican Grill has a market capitalization of $84.14 billion. 
Buying $1000 In CMG: If an investor had bought $1000 of CMG stock 15 years ago, it would be worth $34,170.91 today based on a price of $61.75 for CMG at the time of writing.
<h3>Chipotle Mexican Grill's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734650109_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Chipotle Mexican Grill Stock In The Last 15 Years

Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) has outperformed the market over the past 15 years by 4.07% on an annualized basis producing an average annual return of 15.69%. Currently, Verisk Analytics has a market capitalization of $38.91 billion. 
Buying $100 In VRSK: If an investor had bought $100 of VRSK stock 15 years ago, it would be worth $894.74 today based on a price of $275.58 for VRSK at the time of writing.
<h3>Verisk Analytics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734649208_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRSK

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

Jones Lang LaSalle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JLL#NYSE">JLL</a>) has outperformed the market over the past 20 years by 1.69% on an annualized basis producing an average annual return of 9.89%. Currently, Jones Lang LaSalle has a market capitalization of $11.72 billion. 
Buying $1000 In JLL: If an investor had bought $1000 of JLL stock 20 years ago, it would be worth $6,666.58 today based on a price of $246.93 for JLL at the time of writing.
<h3>Jones Lang LaSalle's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734648313_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Jones Lang LaSalle 20 Years Ago Would Be Worth This Much Today

BlackBerry Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) reported third-quarter financial results after the market close on Thursday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/24/12/ac42605872/blackberry-reports-third-quarter-fiscal-year-2025-results">from the quarter</a>.
Q3 Earnings: BlackBerry reported third-quarter revenue of $162 million. The company reported third-quarter adjusted earnings of two cents per share, beating analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a> for a loss of one cent per share, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
IoT revenue was&nbsp;$62&nbsp;million, up 13% year-over-year.&nbsp;Cybersecurity revenue totaled $93&nbsp;million in the quarter, up 7% year-over-year. Licensing revenue&nbsp;came in at $7&nbsp;million.
Total company gross margin was 74% in the quarter. Operating cash flow improved by $34 million year-over-year to $3 million. BlackBerry ended the quarter with $266 million in&nbsp;cash, cash equivalents and&nbsp;short-&nbsp;and long-term investments.
&#8220;BlackBerry achieved a significant inflection in its results this past quarter. Driven by a combination of strong revenue performance for both our Cybersecurity and IoT divisions, and continued focus on costs and efficiency, the company delivered stronger than expected profitability and a return to positive cash flow ahead of schedule,&#8221; said John Giamatteo, CEO of BlackBerry. 
From Last Week: <a href="https://www.benzinga.com/24/12/42477300/russian-state-backed-hackers-target-ukrainian-military-devices-via-spacexs-starlink-microsoft-report-reveals">Russian State-Backed Hackers Target Ukrainian Military Devices Via SpaceX&#8217;s Starlink, Microsoft Reveals</a>
Guidance: BlackBerry expects fourth-quarter revenue of $126 million to $135 million versus estimates of $161.49 million. The company anticipates fourth-quarter IoT revenue of $60 million to $65 million, secure communications revenue of $62 million to $66 million and licensing and other revenue of approximately $4 million.
BlackBerry expects full-year revenue of $517 million to $526 million versus estimates of $603.12 million. The company anticipates full-year adjusted earnings to be somewhere between breakeven and a loss of two cents per share, versus estimates for a loss of two cents per share.
Management will further discuss the quarter on a call with investors and analysts at 5:30 p.m. ET.
BB Price Action:&nbsp;<a href="https://www.benzinga.com/quote/BB" target="_blank" rel="noreferrer noopener">BlackBerry shares</a>&nbsp;were up 0.17% in after hours, trading at $2.98 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Courtesy of BlackBerry.

Earnings

Movers

Tech

BlackBerry Beats Q3 Earnings Estimates, But Soft Guidance Keeps Shares In Check

Legal

SVCO

Silvaco Says US Court Of Appeals For The Ninth Circuit Affirmed US District Court's Dismissal Of All Claims Brought By Aldini

ALLETE Says FERC Approved Proposed Transaction With CPP Investments And Global Infrastructure Partners

Guidance

PARR

Par Pacific Expects 2025 Capital Expenditure And Turnaround Outlay Guidance Of $210M - $240M

Marsh &amp; McLennan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 10 years by 2.76% on an annualized basis producing an average annual return of 13.69%. Currently, Marsh &amp; McLennan has a market capitalization of $103.31 billion. 
Buying $100 In MMC: If an investor had bought $100 of MMC stock 10 years ago, it would be worth $360.25 today based on a price of $210.35 for MMC at the time of writing.
<h3>Marsh &amp; McLennan's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734647416_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Marsh & McLennan 10 Years Ago Would Be Worth Today

SPRY

ARS Pharmaceuticals Says Express Scripts Has Added neffy (Epinephrine Nasal Spray) To Its Commercial National Formularies

The Stock Repurchase Program will begin on December 19, 2024 and conclude on December 19, 2025.

Buybacks

FRST

Primis Financial Board Approves Stock Repurchase Program For Up To 740,600 Of Outstanding Shares Of Common Stock

As a result of this error, the Bank will record $8.1 million on a pre-tax basis of occupancy expense in the fourth quarter of 2024. On an after-tax basis, this will reduce fourth quarter diluted earnings per share by approximately $0.43.
As for the impact of ASC 842 in future years, it is expected that the correct calculation of lease expense will increase occupancy expense by approximately $1.6 million per year on a pre-tax basis.
It has evaluated the impact to income for each of the periods involved as well as the cumulative impact to 2024's results and have determined the understatement in the prior years as well as the impact to the results for 2024 are not material to the Bank's results of operations or its balance sheet.

PFBC

Preferred Bank Finds Unreconciled Difference In Its Calculation Of Its Right Of Use Asset And Lease Liabilities; Expects Additional Q4 Expense To Reduce Q4 EPS By $0.43

ASAI

Sendas Distribuidora Intends To Proceed With Voluntary Delisting Of Its ADSs From NYSE

BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.01) by 300 percent. This is a 100 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $143.00 million which missed the analyst consensus estimate of $150.76 million by 5.15 percent. This is a 18.29 percent decrease over sales of $175.00 million the same period last year.

BlackBerry Q3 2025 Sales $143.00M Miss $150.76M Estimate

FCPT

Four Corners Property Trust Reports Acquisition Of A MercyOne Outpatient Clinic Property For $2.8M

BlackBerry is providing the following guidance for the fourth quarter and the full fiscal year 2025 (ending February 28, 2025).&nbsp;
As the sale of the Company's Cylance business is expected to close during the fourth quarter of 2024, that business is reported this quarter as discontinued operations, and the following guidance, except for non-GAAP basic EPS, is reflective solely of the expected results of the Company's continuing operations.

BlackBerry Now Expects FY25 Total Revenue Of $517M - $526M (Est $603.12M), Non-GAAP Basic EPS Of $(0.02) - Breakeven (Est $(0.02))

BlackBerry Expects Q4 Total Revenue Of $126M - $135M (Est $161.49M), Non-GAAP Basic EPS Of $(0.01) - $0.01 (Est $0.01)

Arch Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) has outperformed the market over the past 10 years by 5.27% on an annualized basis producing an average annual return of 16.19%. Currently, Arch Capital Group has a market capitalization of $33.48 billion. 
Buying $100 In ACGL: If an investor had bought $100 of ACGL stock 10 years ago, it would be worth $446.81 today based on a price of $88.99 for ACGL at the time of writing.
<h3>Arch Capital Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734646508_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACGL

Here's How Much $100 Invested In Arch Capital Group 10 Years Ago Would Be Worth Today

Cohealyx is designed for tissue integration and revascularization to facilitate wound healing, reduce treatment timelines, and improve patient outcomes in the treatment of full-thickness wounds.

RCEL

AVITA Medical Secures FDA 510(k) Clearance For Cohealyx

Exchange-traded funds are rewriting the financial playbook, with 2024 marking a historic <a href="https://www.benzinga.com/etfs">year for the industry.</a>
From record-breaking flows to innovative fund launches, Bank of America detailed $1.6 trillion in ETF inflows this year in a new note. The global ETF market has grown to a staggering $15.1 trillion in assets under management. 
Additionally, ETF launches hit an all-time high of 1,485 in 2024, and institutional ownership continues to surge, cementing ETFs as the cornerstone of modern investment strategies. 
Here's how the ETF ecosystem is evolving — and why it matters.
<h3 class="wp-block-heading">Record Year for ETF Growth</h3>
The numbers speak for themselves: over the last five years, the global ETF market has grown at a robust 19% annualized rate, amassing more than $15 trillion in assets under management. 
In total, 15,866 ETFs have been created since 1993, with 2024 alone contributing 1,485 of those — a record for both active and U.S.-listed ETFs.
Institutional investors, retail traders and even cash-strapped mutual funds are gravitating toward ETFs for their liquidity, tax efficiency and cost advantages.
<h3 class="wp-block-heading">The Rise of Active ETFs: A Balancing Act</h3>
While ETFs have historically been dominated by passive strategies, active ETFs are making their presence known. Active funds accounted for 18% of total inflows in 2024, signaling a growing appetite for alpha strategies.
Still, passive funds remain the kingpin, representing over 50% of equity fund assets by AUM. 
In fact, 93% of ETFs track some type of index, but the allure of active management is pushing innovation. 
Investors seeking more active strategies in passive funds are also driving mutual fund-to-ETF conversions. According to Bank of America, this trend is likely to accelerate in the coming years as mutual funds struggle to remain relevant.
<h3 class="wp-block-heading">SPY vs. VOO: New ETF Champion in the Making?</h3>
The SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) remains the largest and most actively traded ETF since its inception in 1993. But its throne is being challenged.
Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) has a 6.5-basis-point lower expense ratio compared to SPY and could potentially surpass it in AUM by 2026.
In 2024, VOO registered more than six times the inflows obtained by SPY. 
<h3 class="wp-block-heading">Fund Flows: The Biggest Winners of 2024</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>ETF</th>
<th>Fund Flows YTD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vanguard S&amp;P 500 ETF (VOO)</td>
<td>$122.75 billion</td>
</tr>
<tr>
<td>iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>)</td>
<td>$48.97 billion</td>
</tr>
<tr>
<td>iShares Bitcoin Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NYSE">IBIT</a>)</td>
<td>$37.04 billion</td>
</tr>
<tr>
<td>Vanguard Total Stock Market ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTI#NYSE">VTI</a>)</td>
<td>$29.96 billion</td>
</tr>
<tr>
<td>Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)</td>
<td>$25.38 billion</td>
</tr>
<tr>
<td>iShares Core U.S. Aggregate Bond ETF (AGG)</td>
<td>$20.62 billion</td>
</tr>
<tr>
<td>SPDR Portfolio S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPLG#NYSE">SPLG</a>)</td>
<td>$19.91 billion</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data: TradingView as of Dec. 19, 2024. </figcaption></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42594797/trump-wants-to-get-rid-of-the-debt-ceiling-30-year-treasury-bonds-fall-to-2024-lows-stocks-cut-gains">Trump Would &#8216;Lead The Charge&#8217; To Scrap Debt Ceiling: 30-Year Treasury Bonds Slide To 2024 Lows, Stocks Cut Gains</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Broad U.S. Equity ETFs

Markets

ETFs

IBIT

SPLG

ETF Market Sets Records In 2024 As Inflows Reach $1.6 Trillion: 7 Funds Leading Charge

Vivani Medical GAAP EPS of -$0.10 beats by $0.02

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Vivani Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/vani-stock-quote/">VANI</a>) just reported results for the second quarter of 2024.<ul><li>Vivani Medical reported earnings per share of -10 cents. This was above the analyst estimate for EPS of -12 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/vani-stock-earnings-vivani-medical-for-q2-of-2024/">VANI Stock Earnings: Vivani Medical Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VANI Stock Earnings: Vivani Medical Beats EPS for Q2 2024

Naz Rahman, an analyst from Maxim Group, has initiated a new Buy rating on Vivani Medical (VANI). Naz Rahman has given his Buy rating due to a comb...

Innovative Obesity Treatment Promises High Compliance: Buy Recommendation for Vivani Medical

Maxim Group analyst Naz Rahman reiterated a Buy rating on Vivani Medical (VANI – Research Report) yesterday and set a price target of $8.00. Naz Ra...

Buy Rating Affirmed for Vivani Medical on Strong Potential of NPM-115 Implant for Metabolic Disease Treatment

Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Vivani Medical (VANI – Research Report) and keeping the price target at $8.00. Naz R...

Buy Rating on Vivani Medical: Advancing GLP-1 Therapies with Innovative Implantable Treatment

Catalyst Watch: Netflix earnings, Lenovo tech event, Paris Motor Show, and eyes on oil

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

JPMorgan, Five Below downgraded: Wall Street's top analyst calls

Vivani Medical GAAP EPS of -$0.11

Vivani Medical, Inc. ( ($VANI) ) has released its Q3 earnings. Here is a breakdown of the information Vivani Medical, Inc. presented to its investo...

Vivani Medical Reports Q3 Loss, Advances GLP-1 Trials

Vivani Medical Gains 'Buy' Rating Due to Strategic Advancements and Financial Strength

ADBE

ALGM

ALLY

AVDX

BLNK

BYDDF

CAPR

CROX

CTRI

CYTK

DLTR

FIVE

HUBS

IBTA

INTC

LNVGY

MIRM

MSFT

MTEN

NAPA

NFLX

NRBO

NVDA

NVNO

OCGN

OKTA

QCOM

SCHW

SERV

SFHG

SRPT

SRRK

TSLA

ULTA

USGO

VANI

VLKAF

VRSSF

ZYME

Press Releases

Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024

Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now

Presenting on the Emerging Growth Conference 75 Day 2 on September 26

Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024

Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now

Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now

Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results

Penny Stocks

Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast

Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

AEMD

ASPI

ATWT

BIXT

BNRG

BTVRF

BVAXF

CMCL

CSE:BIOV

CSE:ELEM

CSE:PLUG

CSE:PMC

CYIO

ELMGF

EUDA

GDTC

GIFT

GOEV

GOSS

GOVX

ICON

IMRN

JETR

LDTC

MNMRF

MTWO

NCSM

NRXBF

NVAAF

PCYO

PENMF

PGEZF

PLGGF

PMCCF

RECAF

RGBP

SEVCF

SIGY

SKYH

STXPF

SUGRF

TSX:VGZ

TSX:VOXR

TSXV:BTV

TSXV:MNRG

TSXV:NRX

TSXV:PGE

TSXV:RECO

TSXV:STU

TSXV:SUG

TSXV:XBOT

UMAC

USEG

VIOT

VOXR

XBOTF

Apyx Medical

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

HeartBeam

CytoSorbents

DIH Holding US, Inc. - Class A Common Stock

DIH Holding US

Daxor

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Edap TMS

Fonar

Fractyl Health

Comments

Vivani Medical

Vivani Medical (VANI) オプション

Vivani Medical (NASDAQ:VANI) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル